VV-993

N/A

Report date: 2024/03/21 12:53:24
NME

Base Information

Drug NameVV-993
Drug Alias NameAnti-SARS-CoV-2 3CLpro inhibitor (Shanghai Junshi Biosciences)VV-993JT-003 (Shanghai Junshi Biosciences)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSARS-CoV-2-3C-like-proteinase inhibitors
TargetsSARS-CoV-2-3C-like-proteinase
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesShanghai Institute Of Materia Medica, Chinese Academy Of SciencesWuhan Institute Of Virology, Chinese Academy Of Sciences
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Junshi Biosciences Co Ltd
Inactive CompaniesWuhan Institute Of Virology, Chinese Academy Of SciencesSuzhou Vigonvita Life Sciences Co LtdShanghai Institute Of Materia Medica, Chinese Academy Of Sciences
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A